Evidence map›Paper›PMID 31811336›Full record

ArticleCancer immunology, immunotherapy : CII2020

CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.

Nuray Erin, Sayra Dilmaç, Anna Curry, Özlem Duymuş, Gamze Tanriover, Aaron Prodeus, Jean Gariepy, Reginald M Gorczynski

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Prognostic Value ofCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nuray ErinDepartment of Medical Pharmacology, Immunopharmacology and Immunooncology Research unit, Akdeniz University School of Medicine, B-Blok Kat 1 Immunoloji, 07070, Antalya, Turkey. nerin@akdeniz.edu.tr.ORCID http://orcid.org/0000-0002-6116-1970
Sayra DilmaçDepartment of Histology and Embryology, Akdeniz University School of Medicine, Antalya, Turkey.
Anna CurryUniversity Health Network, Toronto General Hospital, Toronto, Canada.
Özlem DuymuşDepartment of Medical Pharmacology, Immunopharmacology and Immunooncology Research unit, Akdeniz University School of Medicine, B-Blok Kat 1 Immunoloji, 07070, Antalya, Turkey.
Gamze TanrioverDepartment of Histology and Embryology, Akdeniz University School of Medicine, Antalya, Turkey.
Aaron ProdeusSunnybrook Cancer Centre, Toronto General Hospital, Toronto, Canada.
Jean GariepySunnybrook Cancer Centre, Toronto General Hospital, Toronto, Canada.
Reginald M GorczynskiUniversity Health Network, Toronto General Hospital, Toronto, Canada.
Akdeniz University · TRToronto General Hospital · CAUniversity Health Network · CA

Funding

Akdeniz Üniversitesi TUA-2015-585
6 · The paper itself

Abstract

We previously reported that CD200 overexpression in the host decreases progression and metastasis of the highly aggressive metastatic 4THM breast carcinoma. We have explored a possible synergistic interaction between the CD200 mimetic PEG-M49 and pegylated liposomal doxorubicin (Peg-Dox) in wild-type CD200 knockout (CD200

Indexed as

AnimalsAntigens, CDAntineoplastic Combined Chemotherapy ProtocolsAptamers, NucleotideBreast NeoplasmsCell Line, TumorDisease Models, AnimalDoxorubicinDrug SynergismFemaleHumansMiceMice, Inbred BALB CMice, KnockoutOrexin ReceptorsPolyethylene GlycolsAntigens, CDantigens, CD200Aptamers, NucleotideCd200r1 protein, mouseDoxorubicinliposomal doxorubicinOrexin ReceptorsPolyethylene GlycolsAptamerBreast cancerCD200DoxorubicinMDSCMetastasis

Identifiers

PMID31811336
PMCPMC11027860
OpenAlexW2992202553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.